Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Photo of Peter M. Hecht
Individual Investor

Peter M. Hecht

Overview

Edit Overview Section
Number of Portfolio Companies 2
Number of Exits 
Unlock for free
  • Investor Type 
    obfuscation
  • Number of Exits 
    obfuscation
Peter Hecht is the Co-Founder and CEO of Cyclerion Therapeutics. He previously worked at Ironwood Pharmaceuticals as a Co-Founder and CEO. Peter Hecht attended the University of California, Berkeley.

Personal Investments

Edit Personal Investments Section
Number of Investments 3
Peter M. Hecht has made 3 investments. Their latest investment was Series A - Tisento Therapeutics on
obfuscation
, when Tisento Therapeutics raised
obfuscation
.
Announced Date  
Organization Name  
Lead Investor  
Funding Round  
Money Raised  
obfuscation
Tisento Therapeutics Logo
Tisento Therapeutics
—
Series A - Tisento Therapeutics Logo
Series A - Tisento Therapeutics
obfuscation
obfuscation
Cyclerion Therapeutics Logo
Cyclerion Therapeutics
Yes
Post-IPO Equity - Cyclerion Therapeutics Logo
Post-IPO Equity - Cyclerion Therapeutics
obfuscation
obfuscation
Cyclerion Therapeutics Logo
Cyclerion Therapeutics
—
Post-IPO Equity - Cyclerion Therapeutics Logo
Post-IPO Equity - Cyclerion Therapeutics
obfuscation

Exits

Edit Exits Section
Number of Exits 
Unlock for free
Peter M. Hecht has
obfuscation
exit - Cyclerion Therapeutics. Peter M. Hecht has
obfuscation
exits. Their most notable exits are Cyclerion Therapeutics.

Jobs

Edit Jobs Section
Number of Current Jobs 2
Number of Past Jobs 1
Peter M. Hecht has 2 current jobs as Co-Founder & CEO at Cyclerion Therapeutics and Founder at Tisento Therapeutics. Additionally, Peter M. Hecht has had 1 past job as the Co-Founder and CEO at Ironwood Pharmaceuticals.
Organization Name  
Title At Company  
Start Date  
End Date  
Ironwood Pharmaceuticals Logo
Ironwood Pharmaceuticals
Co-Founder and CEO19982019

Board and Advisor Roles

Edit Board and Advisor Roles Section
Number of Current Board & Advisor Roles 3
Peter M. Hecht holds 3 board and advisor roles including Board Member at Kallyope, Advisory Board Membe at Ariadne Labs, and Board Member at Mythic Therapeutics.

Related Hubs

Edit Related Hubs Section
Hub Name  
CB Rank (Hub)  
Companies That Exited in 2019 (Top 10K) Logo
Companies That Exited in 2019 (Top 10K)
1,279
Greater Boston Area Acquired Companies With Fewer Than 100 Employees Logo
Greater Boston Area Acquired Companies With Fewer Than 100 Employees
15,727
Massachusetts Pharmaceutical Companies Logo
Massachusetts Pharmaceutical Companies
37,995
Cambridge Companies With More Than $10M in Revenue Logo
Cambridge Companies With More Than $10M in Revenue
56,890
Greater Boston Area Acquired Companies With More Than $1M in Revenue Logo
Greater Boston Area Acquired Companies With More Than $1M in Revenue
18,527
Biotechnology Acquired Companies With Fewer Than 10 Employees Logo
Biotechnology Acquired Companies With Fewer Than 10 Employees
35,747
Cambridge Companies that Exited Logo
Cambridge Companies that Exited
39,176
Northeastern US Acquired Companies With Fewer Than 100 Employees Logo
Northeastern US Acquired Companies With Fewer Than 100 Employees
1,758
Massachusetts Acquired Companies With More Than $10M in Revenue Logo
Massachusetts Acquired Companies With More Than $10M in Revenue
28,198
Massachusetts Acquired Companies With Less Than $1B in Revenue Logo
Massachusetts Acquired Companies With Less Than $1B in Revenue
16,057

Education

Edit Education Section
Peter M. Hecht studied at Stanford University, University of California Berkeley, and  Stanford University.

Recent News and Activity

Edit Recent News and Activity Section
Number of News Articles 2
News•Aug 4, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Funding Round•Jul 31, 2023
Tisento Therapeutics raised
obfuscation
from Invus and 5 other investors
Discover more funding rounds
Funding Round•May 25, 2023
Cyclerion Therapeutics raised
obfuscation
from Peter M. Hecht
Discover more funding rounds
Funding Round•Jun 4, 2021
Cyclerion Therapeutics raised
obfuscation
from EcoR1 Capital and 6 other investors
Discover more funding rounds
News•Oct 14, 2020
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(540e82b 1)
|